Cardiff Oncology's (CRDF) Outperform Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of Cardiff Oncology (NASDAQ:CRDF - Free Report) in a report issued on Wednesday,RTT News reports.

Separately, HC Wainwright raised their price objective on shares of Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, May 9th.

Cardiff Oncology Trading Up 2.6%

NASDAQ CRDF traded up $0.08 on Wednesday, reaching $3.10. The stock had a trading volume of 1,495,258 shares, compared to its average volume of 1,189,323. Cardiff Oncology has a 1 year low of $2.01 and a 1 year high of $5.64. The business has a 50 day moving average price of $3.09 and a 200 day moving average price of $3.54. The company has a market capitalization of $206.24 million, a price-to-earnings ratio of -3.37 and a beta of 1.61.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.09 million. Cardiff Oncology had a negative return on equity of 76.45% and a negative net margin of 8,308.50%. On average, analysts anticipate that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cardiff Oncology

A number of large investors have recently modified their holdings of CRDF. BNP Paribas Financial Markets bought a new position in shares of Cardiff Oncology in the 4th quarter valued at about $25,000. Ledgewood Wealth Advisors LLC bought a new position in Cardiff Oncology during the first quarter worth about $35,000. Belpointe Asset Management LLC bought a new position in Cardiff Oncology during the first quarter worth about $37,000. Castleview Partners LLC acquired a new position in Cardiff Oncology during the first quarter worth approximately $45,000. Finally, ProShare Advisors LLC bought a new stake in Cardiff Oncology in the fourth quarter valued at approximately $50,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.